(AGI) Madrid, Sept 29 - The combined use of cobimetinib andvemurafenib can cut the risk of malignant melanoma metastasesby half, phase III clinical data suggests. The findings werepresented in Madrid on Monday at the annual conference of theEuropean Society for Medical Oncology. More than 1,800 Italiansdie of skin cancer metastases every year, and the number ofpeople diagnosed with skin cancer has risen significantly. . .